Chong Kun Dang Launches 'Cantabel A', a Triple Combination Drug for Hypertension and Dyslipidemia
Chong Kun Dang's Triple Combination Drug for Hypertension and Dyslipidemia, 'Cantabel-A'
View original image[Asia Economy Reporter Lee Chun-hee] Chong Kun Dang recently announced on the 3rd that it has launched 'Cantabel A,' a triple combination drug for hypertension and dyslipidemia.
Cantabel A is a product combining candesartan from the angiotensin II receptor blocker (ARB) class, amlodipine from the calcium channel blocker (CCB) class for hypertension treatment, and atorvastatin for dyslipidemia treatment. Cantabel A is the first triple combination drug of these ingredients in Korea.
Chong Kun Dang demonstrated the efficacy of Cantabel A for treating dyslipidemia and hypertension through a Phase 3 clinical trial conducted from 2018 to 2019 at 17 institutions in Korea. A total of 154 patients with hypertension accompanied by dyslipidemia were divided into three groups: Cantabel A administration group, candesartan + amlodipine combination group, and candesartan + atorvastatin co-administration group. After 8 weeks of drug administration, the Cantabel A group showed a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) levels compared to the control groups, and an improvement in mean systolic blood pressure (MSSBP) changes was also observed.
Chong Kun Dang launched Cantabel A in five different dosages?candesartan/amlodipine/atorvastatin at 8/5/10 mg, 8/5/20 mg, 16/5/10 mg, 16/5/20 mg, and 16/10/40 mg?allowing tailored prescriptions according to patient symptoms while also addressing the inconvenience of dose adjustment in fixed-dose combination (FDC) drugs.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- Samsung Enterprise Labor Union: "We Respect Court’s Injunction Decision... General Strike to Proceed on the 21st as Planned"
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- [Exclusive] With Budget Safeguard Gone, Digital Learning Center May Be Reduced or Disappear in Financially Weaker Local Governments
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
A representative from Chong Kun Dang stated, "Cantabel A is the first triple combination drug introduced in Korea, providing a new treatment option for patients with hypertension accompanied by dyslipidemia. The domestic market lacks combination drugs based on atorvastatin, so we expect this to improve medication adherence among hypertensive patients taking this drug."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
